Ferrous Fumarate

證據等級: L5

預測適應症: 1 個

Ferrous Fumarate: From Iron Deficiency Anaemia to Non-Syndromic Esophageal Malformation

One-Sentence Summary

Ferrous fumarate is an oral iron salt conventionally used to correct iron-deficiency anaemia. The TxGNN model predicts a possible association with non-syndromic esophageal malformation, but this prediction is currently supported by zero clinical trials and zero publications, and no plausible pharmacological mechanism links an iron supplement to a structural congenital defect of the esophagus.

Quick Overview

Item	Content
Original Indication	Iron deficiency anaemia (general pharmacological classification — no SAHPRA licence text is available to confirm the approved indication)
Predicted New Indication	Non-syndromic esophageal malformation
TxGNN Prediction Score	99.49%
Evidence Level	L5
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for ferrous fumarate in this evidence pack. Based on general pharmacological knowledge, ferrous fumarate is an oral ferrous iron salt used to replenish iron stores and support haemoglobin synthesis in patients with iron deficiency or iron-deficiency anaemia. Its pharmacology is limited to intestinal iron absorption and downstream erythropoiesis.

Non-syndromic esophageal malformation is a structural congenital anomaly arising from a defect in tracheoesophageal septation during embryonic development, and it is managed surgically rather than pharmacologically. There is no known biological pathway — nutritional, haematological, or otherwise — by which iron repletion would influence esophageal embryogenesis or structural correction after birth.

Given this, the very high TxGNN score (99.49%) most likely reflects a statistical artefact of the knowledge-graph embedding (e.g., node-degree bias or spurious co-occurrence patterns) rather than a genuine biological signal. Combined with the complete absence of supporting original-indication, MOA, and safety data for this drug, the evidentiary basis for this prediction is weak and does not currently warrant further mechanistic or clinical investigation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Ferrous fumarate is not currently registered with SAHPRA (0 registrations found), and no market or licence information is available for this evidence pack.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication has no supporting clinical trials or literature, no plausible mechanistic link to the drug’s known pharmacology, and the drug itself lacks confirmed original-indication, MOA, and South African regulatory data. The TxGNN score alone (L5 evidence, model prediction only) is insufficient to justify further evaluation.

To proceed, the following is needed:

SAHPRA-approved Professional Information (PI) with warnings, contraindications, and drug interaction data
Confirmed original indication and mechanism of action (MOA) documentation
Independent biological or mechanistic rationale linking iron supplementation to esophageal malformation, if one exists
Any emerging clinical trial or literature evidence for this specific drug–disease pair
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.